|Mr. Douglas Arthur Doerfler||Founder, Pres, CEO & Exec. Director||1.39M||N/A||1956|
|Mr. Ronald Evan Holtz CPA, Ph.D.||Chief Financial Officer||649.38k||N/A||1958|
|Dr. J. Stark Thompson Ph.D.||Consultant||84.71k||N/A||1942|
|Dr. Cenk Sumen||Chief Scientific Officer||N/A||N/A||1973|
|Mr. Sean Menarguez||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Maher Masoud||Exec. VP, Gen. Counsel & Sec.||N/A||N/A||1975|
|Mr. Thomas Michael Ross||Exec. VP of Global Sales||N/A||N/A||1961|
|Dr. James Brady Ph.D.||Sr. VP of Technical Applications & Customer Support||N/A||N/A||N/A|
|Dr. Sarah Haecker Meeks Ph.D.||Sr. VP of Bus. Devel.||N/A||N/A||N/A|
|Mr. James Lovgren||Sr. VP of Global Marketing||N/A||N/A||N/A|
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte, Inc.’s ISS governance QualityScore as of 31 July 2022 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 8; Compensation: 8.